ChiCTR2000038210 版本V1.7 版本创建时间2020/11/30 11:46:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038210 

最近更新日期:

Date of Last Refreshed on:

2020-11-30 11:46:10 

注册时间:

Date of Registration:

2020-09-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

影像和代谢标记物预测青少年抑郁症预后复发的研究

Public title:

Imaging and metabolic biomarkers predicting recurrent depressive disorder in adolescents

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于静息态功能磁共振成像和新一代代谢组学的抑郁症预后复发机制研究

Scientific title:

Studies on the underlying mechanisms of recurrent depressive disorder using the combination of functional magnetic resonance imaging (fMRI) and next-generation metabolomics

研究课题代号(代码):

Study subject ID:

山西省自然科学基金 (201901D221113)

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨志云 

研究负责人:

李俊峰 

Applicant:

Zhiyun Yang 

Study leader:

Junfeng Li 

申请注册联系人电话:

Applicant telephone:

+86 13521253262

研究负责人电话:

Study leader's
telephone:

+86 13503551369

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

likefeng@czmc.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

lijunfeng@czmc.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山西省长治市延安南路110号

研究负责人通讯地址:

山西省长治市延安南路110号

Applicant address:

110 Yan'an Road South, Changzhi, Shanxi, China

Study leader's address:

110 Yan'an Road South, Changzhi, Shanxi, China

申请注册联系人邮政编码:

Applicant postcode:

046000

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长治医学院附属和平医院

Applicant's institution:

Heping Hospital Affiliated to Changzhi Medical College

研究负责人所在单位:

长治医学院附属和平医院

Affiliation of the Leader:

Heping Hospital Affiliated to Changzhi Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20190925

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

长治医学院伦理委员会

Name of the ethic committee:

Ethics committee of Changzhi Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2019-09-25 00:00:00

伦理委员会联系人:

郭婷婷

Contact Name of the ethic committee:

Tingting Guo

伦理委员会联系地址:

山西省长治市城区延安南路110号 长治医学院附属和平医院医务科

Contact Address of the ethic committee:

Medical Department, Heping Hospital, Changzhi Medical College, 110 Yan'an Road South, Changzhi, Shanxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13834777444

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长治医学院附属和平医院

Primary sponsor:

Heping Hospital Affiliated to Changzhi Medical College

研究实施负责(组长)单位地址:

长治医学院附属和平医院

Primary sponsor's address:

110 Yan'an Road South, Changzhi, Shanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山西

市(区县):

长治

Country:

China

Province:

Shanxi

City:

Changzhi

单位(医院):

长治医学院附属和平医院

具体地址:

长治市延安南路110号

Institution
hospital:

Heping Hospital Affiliated to Changzhi Medical College

Address:

110 Yan'an Road South

经费或物资来源:

山西省自然科学基金 (201901D221113)

Source(s) of funding:

Natural Science Foundation of Shanxi Province (201901D221113)

研究疾病:

抑郁症  

Target disease:

Depression

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

本研究的主要目的为揭示青少年抑郁症复发的机制,寻找预测青少年抑郁症复发的影像和代谢生物标记物。  

Objectives of Study:

To investigate the imaging and metabolic biomarkers for predicting the recurrence of depression (rsMDD) in adolescent and to elucidate the underlying mechanisms of rsMDD.

药物成份或治疗方案详述:

诊断性试验,不涉及药物或者其他治疗。 

Description for medicine or protocol of treatment in detail:

Diagnostic tests, not involving drugs or other treatments. 

纳入标准:

病例组:
1. 年龄在10 - 19 岁;
2. 汉密尔顿抑郁症量表(HAMD-17)>= 16;
3. 未服药或者经历了至少5个药物半衰期的洗脱期。

对照组:
1. 年龄在10 - 19 岁
2. 汉密尔顿抑郁症量表(HAMD-17)<= 7。

Inclusion criteria

Case group:
1. Patients aged 10-19 years;
2. Hamilton Depression Scale (HAMD-17) >= 16;
3. Patients who are not taking medication or have experienced a washout period of at least five drug half lives.
In the control group, there was no significant difference between the two groups
1. Patients aged 10-19 years;
2. Hamilton Depression Scale (HAMD-17) <= 7.

排除标准:

病例组排除标准:
1. 患有其他精神疾病、癫痫、双向抑郁等;
2. 磁共振扫描禁忌 (带有心脏起搏器、神经刺激器者、人工金属心脏瓣膜等的患者)。
对照组排除标准:
1. 患者既往有脑损伤或脑外科手术史;
2. 磁共振扫描禁忌 (带有心脏起搏器、神经刺激器者、人工金属心脏瓣膜等的患者)。

Exclusion criteria:

The exclusion criteria of case group were as follows
1. Patients with other mental diseases, epilepsy, bipolar depression, etc;
2. Patients with contraindication of MRI scanning (patients with pacemaker, nerve stimulator, artificial metal heart valve, etc.).
The exclusion criteria of the control group were as follows
1. Patients with previous history of brain injury or brain surgery;
2. Patients with contraindication of MRI scanning (patients with pacemaker, nerve stimulator, artificial metal heart valve, etc.).

研究实施时间:

Study execute time:

From 2020-10-07 00:00:00 To 2022-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-07 00:00:00 To 2020-11-10 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

1.符合美国精神病学协会精神疾病诊断与统计手册第五版抑郁症诊断的症状学、疾病严重程度以及病程标准。 2.汉密尔顿HAMD-17量表分数,>=16 为抑郁症。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

1. Meet the symptomatic, disease severity and course criteria of depression diagnosis in the fifth edition of the American Psychiatric Association diagnostic and Statistical Manual of mental illness. 2. Hamilton HAMD-17 score >= 16.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

1. 脑区功能连接 2. 血清代谢产物

Index test:

1. Brain connectivity 2. Plasma metabolome

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

初诊未服药的抑郁症患者

例数:

Sample size:

50

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients with newly diagnosed depression

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

双相情感病人

例数:

Sample size:

50

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Patients with bipolar

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山西 

市(区县):

长治 

Country:

China

Province:

Shanxi

City:

Changzhi

单位(医院):

长治医学院附属和平医院 

单位级别:

三甲 

Institution
hospital:

Heping Hospital Affiliated to Changzhi Medical College

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脑连接

指标类型:

主要指标

Outcome:

Brain connectivity

Type:

Primary indicator

测量时间点:

测量方法:

功能磁共振

Measure time point of outcome:

Measure method:

fMRI

指标中文名:

血清代谢组

指标类型:

次要指标

Outcome:

Plasma metabolome

Type:

Secondary indicator

测量时间点:

测量方法:

高效液相串联质谱

Measure time point of outcome:

Measure method:

LC-MS/MS

指标中文名:

SEN, SPE, ACC, AUC of ROC,PPV, NPV

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC,PPV, NPV

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

不采集

Sample Name:

Blood

Tissue:

Not collected

人体标本去向

使用后保存  

说明

保存于长治医学院-80度冰箱

Fate of sample:

Preservation after use  

Note:

Stored in -80C freezer in Changzhi Medical College

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 10 years
最大 Max age 19 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放

Blinding:

open-label

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022-11-01

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Nov 11th, 2022

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF和EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-09-13 23:13:11